GMED has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GMED has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Globus Medical's gross profit for the three months ended in Sep. 2024 was $355 Mil. Globus Medical's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was $1,441 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Globus Medical's gross profit for the three months ended in Sep. 2024 was $355 Mil. Globus Medical's Revenue for the three months ended in Sep. 2024 was $626 Mil. Therefore, Globus Medical's Gross Margin % for the quarter that ended in Sep. 2024 was 56.77%.
Globus Medical had a gross margin of 56.77% for the quarter that ended in Sep. 2024 => Durable competitive advantage
During the past 13 years, the highest Gross Margin % of Globus Medical was 77.64%. The lowest was 58.14%. And the median was 75.92%.
Warning Sign:
Globus Medical Inc gross margin has been in long-term decline. The average rate of decline per year is -2.7%.
The historical data trend for Globus Medical's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Globus Medical Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Gross Profit | Get a 7-Day Free Trial | 605.39 | 571.58 | 718.88 | 759.12 | 1,020.30 |
Globus Medical Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Gross Profit | Get a 7-Day Free Trial | 248.25 | 351.05 | 365.18 | 369.65 | 355.19 |
For the Medical Devices subindustry, Globus Medical's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Globus Medical's Gross Profit distribution charts can be found below:
* The bar in red indicates where Globus Medical's Gross Profit falls into.
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Globus Medical's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as
Gross Profit (A: Dec. 2023 ) | = | Revenue | - | Cost of Goods Sold |
= | 1568.476 | - | 548.174 | |
= | 1,020 |
Globus Medical's Gross Profit for the quarter that ended in Sep. 2024 is calculated as
Gross Profit (Q: Sep. 2024 ) | = | Revenue | - | Cost of Goods Sold |
= | 625.705 | - | 270.515 | |
= | 355 |
Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,441 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
Globus Medical's Gross Margin % for the quarter that ended in Sep. 2024 is calculated as
Gross Margin % (Q: Sep. 2024 ) | = | Gross Profit (Q: Sep. 2024 ) | / | Revenue (Q: Sep. 2024 ) |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | 355 | / | 625.705 | |
= | 56.77 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Globus Medical (NYSE:GMED) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Globus Medical had a gross margin of 56.77% for the quarter that ended in Sep. 2024 => Durable competitive advantage
Thank you for viewing the detailed overview of Globus Medical's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Kelly Huller | officer: SVP, General Counsel | 2560 GENERAL ARMISTEAD AVENUE, AUDOBON PA 19403 |
Dan Lemaitre | director | 2 MUSICK, IRVINE CA 92618 |
David D Davidar | director, officer: Vice President, Operations | C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403 |
Daniel T Scavilla | officer: Senior VP and CFO | C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403 |
Ann D Rhoads | director | 4000 NORTH FIRST STREET, SAN JOSE CA 95134 |
Leslie V Norwalk | director | C/O 3661 VALLEY CENTRE DRIVE SUITE 200, SAN DIEGO CA 92130 |
Dan Wolterman | director | 3721 VALLEY CENTRE DR, SUITE 500, SAN DIEGO CA 92130 |
John A Deford | director | C R BARD INC, 730 CENTRAL AVENUE, MURRAY HILL NJ 07974 |
Keith W Pfeil | officer: SVP, Chief Financial Officer | GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403 |
James R Tobin | director | C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
David M Demski | director, officer: President and COO | C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403 |
Robert Andrew Douglas | director | 21 ATTUNGA ROAD, NEWPORT, NEW SOUTH WALES C3 2106 |
Stephen T Zarrilli | director | FIBERLINK COMMUNICATIONS CORP., 794 PENLLYN PIKE, BLUE BELL PA 19422 |
Anthony L Williams | officer: Senior VP of Bus. Devel. & GC | C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403 |
Steven Payne | officer: Chief Accounting Officer | C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403 |
From GuruFocus
By Business Wire • 08-26-2024
By PRNewswire • 09-17-2024
By PRNewswire • 08-26-2024
By Marketwired • 08-21-2024
By GuruFocus News • 10-15-2024
By GuruFocus News • 11-06-2024
By Marketwired • 10-18-2024
By PRNewswire • 08-18-2024
By Marketwired • 08-21-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.